

Our ref: IG/FOI/FOI.068.24

30 October 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

## Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 23 October 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and my response follows.

### Your Freedom of Information (FOI) Request:

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?
2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

- FCR (fludarabine + cyclophosphamide + rituximab)
- FR (fludarabine + rituximab)
- BR (bendamustine + rituximab)

Pencadlys  
Tŷ Glasbury, Ysbyty Bronllys,  
Aberhonddu, Powys LD3 0LU  
Ffôn: 01874 711661



Headquarters  
Glasbury House, Bronllys Hospital  
Brecon, Powys LD3 0LU  
Tel: 01874 711661

- Bendamustine monotherapy
- RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
- Obinutuzumab ± chlorambucil
- Rituximab + chlorambucil
- Ofatumumab
- Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window.

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	
FR	
BR	
Bendamustine monotherapy	
R-CHOP	
Obinutuzumab ± chlorambucil	
Rituximab + chlorambucil	
Chlorambucil monotherapy	
Rituximab monotherapy	
Ofatumumab	
Other – please specify	

#### Powys Response:

Q1 – Q3. I can confirm Powys Teaching Health Board (PTHB) does not treat any patients with Chronic Lymphocytic Leukaemia (CLL). PTHB is a non-acute care provider, and therefore does not directly provide these services. PTHB commissions cancer services from several Welsh health boards and English provider organisations. I therefore recommend that you contact the providers from whom the health board commissions services:

Health Trust/Organisation	FOI Contact Details
Gloucester Hospitals NHS Foundation Trust	<a href="mailto:ghn-tr.foi@nhs.net">ghn-tr.foi@nhs.net</a>
Shrewsbury & Telford Hospital NHS Trust	<a href="mailto:sath.foi@nhs.net">sath.foi@nhs.net</a>
The Royal Wolverhampton NHS Trust	<a href="mailto:rwh-tr.foi@nhs.net">rwh-tr.foi@nhs.net</a>
Wye Valley NHS Trust	<a href="mailto:Freedom.Information@wvt.nhs.uk">Freedom.Information@wvt.nhs.uk</a>

Health Board/ Organisation	FOI Contact Details
Aneurin Bevan University Health Board	<a href="mailto:FOI.ABB@wales.nhs.uk">FOI.ABB@wales.nhs.uk</a>
Betsi Cadwaladr University Health Board	<a href="mailto:bcu.foi@wales.nhs.uk">bcu.foi@wales.nhs.uk</a>
Cardiff & Vale University Health Board	<a href="mailto:FOI.Requests@wales.nhs.uk">FOI.Requests@wales.nhs.uk</a>
Cwm Taf Morgannwg University Health Board	<a href="mailto:Freedomofinformation@wales.nhs.uk">Freedomofinformation@wales.nhs.uk</a>
Hywel Dda University Health Board	<a href="mailto:FOI.hyweldda@wales.nhs.uk">FOI.hyweldda@wales.nhs.uk</a>
Swansea Bay University Health Board	<a href="mailto:FOIA.Requests@wales.nhs.uk">FOIA.Requests@wales.nhs.uk</a>
Velindre University Health Board	<a href="mailto:Foi.vunhst@wales.nhs.uk">Foi.vunhst@wales.nhs.uk</a>

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via [powysfoi.foi@wales.nhs.uk](mailto:powysfoi.foi@wales.nhs.uk)

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



**Richard Stratton**  
**Assistant Medical Director-Primary Care**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.